Previous studies have shown that about 15%-20% of patients with colorectal cancer carry PIK3CA activation mutations, and patients with PI3KCA mutations have better OS and progression-free survival (PFS) [34]. This evidence concerns the gene PIK3CA and colorectal cancer.